The UK’s NICE approved reimbursement for Genmab’s cervical cancer ADC tisotumab vedotin (Tivdak), reversing an earlier draft stance that raised cost-effectiveness concerns. NICE said the company agreed a confidential discount with NHS England, reducing the effective cost versus the list price. The decision follows UK MHRA approval in December 2025 for recurrent or metastatic cervical cancer, based on Phase 3 evidence showing improved overall survival and progression-free survival versus chemotherapy. NICE cited uncertainty in modeling for earlier draft guidance, noting the discount mitigates those concerns. For Genmab and oncology access teams, the reimbursement clearance matters as the treatment is positioned for patients whose disease recurred or progressed after prior therapy and for whom limited options remain. NICE’s guidance now sets the stage for wider NHS coverage planning in the UK.